• Tectonic Therapeutic Inc TECX.OQ reported a quarterly adjusted loss of $1.20​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-5.28. The mean expectation of three analysts for the quarter was for a loss of 82 cents per share. Wall Street expected results to range from -95 cents to -70 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Tectonic Therapeutic Inc's reported EPS for the quarter was a loss of $1.20​.

• The company reported a quarterly loss of $17.72 million.

• Tectonic Therapeutic Inc shares had risen by 48.0% this quarter and gained 174.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 6.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Tectonic Therapeutic Inc is 55.00

This summary was machine generated from LSEG data November 8 at 05:15 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)